Tianjin Medical University Genral Hospital
Welcome,         Profile    Billing    Logout  
 10 Trials 
9 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Wei
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting
4
466
RoW
Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638
The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.
Renal Insufficiency, Chronic
10/25
03/26
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Active, not recruiting
3
488
RoW
BAT5906 injection, Lucentis
Bio-Thera Solutions
Neovascular (Wet) Age-related Macular Degeneration
04/24
06/25
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting
2
186
RoW
Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, SLE
08/25
05/26
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Terminated
2
195
RoW
TQH3821 tablets 200 mg, TQH3821 tablets matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
01/25
01/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
BAT5906-003-CR, NCT04772105: Clinical Study of the Safety and Efficacy of BAT5906 Injection

Completed
1/2
60
RoW
2.5mg of BAT5906, 4.0mg of BAT5906
Bio-Thera Solutions
Diabetic Macular Edema
11/23
11/23
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed
1
92
RoW
Telitacicept, RC18, standard therapy
RemeGen Co., Ltd.
Systemic Lupus Erythematosus
10/23
11/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Wei
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting
4
466
RoW
Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638
The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.
Renal Insufficiency, Chronic
10/25
03/26
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Active, not recruiting
3
488
RoW
BAT5906 injection, Lucentis
Bio-Thera Solutions
Neovascular (Wet) Age-related Macular Degeneration
04/24
06/25
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting
2
186
RoW
Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, SLE
08/25
05/26
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Terminated
2
195
RoW
TQH3821 tablets 200 mg, TQH3821 tablets matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
01/25
01/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
BAT5906-003-CR, NCT04772105: Clinical Study of the Safety and Efficacy of BAT5906 Injection

Completed
1/2
60
RoW
2.5mg of BAT5906, 4.0mg of BAT5906
Bio-Thera Solutions
Diabetic Macular Edema
11/23
11/23
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed
1
92
RoW
Telitacicept, RC18, standard therapy
RemeGen Co., Ltd.
Systemic Lupus Erythematosus
10/23
11/23

Download Options